Treatment outcomes following continuous miglustat therapy in
Por um escritor misterioso
Last updated 25 abril 2025

Background Niemann-Pick disease Type C (NP-C) is a rare, progressive neurodegenerative disorder characterized by progressive neurodegeneration and premature death. We report data at closure of the NPC Registry that describes the natural history, disease course and treatment experience of NP-C patients in a real-world setting. Methods The NPC Registry was a prospective observational cohort study that ran between September 2009 and October 2017. Patients with a confirmed diagnosis of NP-C were enrolled regardless of treatment status. All patients underwent clinical assessments and medical care as determined by their physicians; data were collected through a secure internet-based portal. Results At closure on October 19, 2017, 472 patients from 22 countries were enrolled in the NPC Registry. Mean (standard deviation) age at enrollment was 21.2 (15.0) years, and 51.9% of patients were male. First neurological symptom onset occurred during the early-infantile (< 2 years), late-infantile (2 to < 6 years), juvenile (6 to < 15 years), or adolescent/adult (≥ 15 years) periods in 13.5, 25.6, 31.8, and 29.1% of cases, respectively. The most frequent neurological manifestations prior to enrollment included ataxia (67.9%), vertical supranuclear gaze palsy (67.4%), dysarthria (64.7%), cognitive impairment (62.7%), dysphagia (49.1%), and dystonia (40.2%). During infancy, splenomegaly and hepatomegaly were frequent (n = 199/398 [50%] and n = 147/397 [37.0%], respectively) and persisted in most affected patients. Of the 472 enrolled patients, 241 were continuously treated with miglustat during the NPC Registry observation period, of whom 172 of these 241 patients were treated continuously for ≥12 months. A composite disability score that assesses impairment of ambulation, manipulation, language, and swallowing was highest in the early-infantile population and lowest in the adolescent/adult population. Among the continuous miglustat therapy population, 70.5% of patients had improved or had stable disease (at least 3 of the 4 domains having a decreased or unchanged score between enrollment and last follow-up). The NPC Registry did not identify any new safety signals associated with miglustat therapy. Conclusions The profiles of clinical manifestations in the final NPC Registry dataset agreed with previous clinical descriptions. Miglustat therapy was associated with a stabilization of neurological manifestations in most patients. The safety and tolerability of miglustat therapy was consistent with previous reports.

Safety and efficacy of cipaglucosidase alfa plus miglustat versus

Heat shock protein amplification improves cerebellar myelination

PDF) Treatment outcomes following continuous miglustat therapy in

Precision medicine for genetic childhood movement disorders - Soo

Treatment-emergent adverse events* during 24 months of miglustat

Randomized, controlled trial of miglustat in Gaucher's disease

Correlation of age of onset and clinical severity in Niemann–Pick

Long‐term efficacy of miglustat in paediatric patients with

Cost-effectiveness of miglustat versus symptomatic therapy of

PDF) Treatment outcomes following continuous miglustat therapy in

Long term follow-up to evaluate the efficacy of miglustat

PDF] Review of miglustat for clinical management in Gaucher

Therapies and Upcoming Treatments

Frontiers Therapeutic Strategies For Tay-Sachs Disease
Recomendado para você
-
Parents of kids with Niemann Pick C advocate for adrabetadex25 abril 2025
-
Miglustat in Niemann-Pick disease type C patients: a review, Orphanet Journal of Rare Diseases25 abril 2025
-
Rare Diseases Research: Clinical Trial for Niemann-Pick Type C25 abril 2025
-
NNPDF on X: October is Global Niemann-Pick Disease Awareness25 abril 2025
-
Niemann–Pick disease25 abril 2025
-
Diagnostic and predictive methods for a Niemann-Pick disease type25 abril 2025
-
Niemann-Pick disease A or B in four pediatric patients and SMPD125 abril 2025
-
Hepatocellular carcinoma as a complication of Niemann‐Pick disease25 abril 2025
-
Gene therapy shows promise for treating Niemann-Pick disease type25 abril 2025
-
Niemann-Pick Disease Concise Medical Knowledge25 abril 2025
você pode gostar
-
Light Novel: Volume 11, Slave Harem in the Labyrinth of the Other World Wiki25 abril 2025
-
FINAL GAME, Lei v. Muzychuk25 abril 2025
-
Sonic Mania: How Sega can fix it25 abril 2025
-
Turma da Mônica - A Mônica não é a única dentuça no universo25 abril 2025
-
Descubra e compartilhe as mais belas imagens de todo o mundo25 abril 2025
-
egwdota2 (@egwdota2) / X25 abril 2025
-
TryHackMe King of the Hill - lion25 abril 2025
-
Asus ROG Ally Is Now Available: A $700 Handheld Powerhouse25 abril 2025
-
End of an era: The next 'Super Mario' doesn't have a Game Over25 abril 2025
-
Btd5 Unblocked Games25 abril 2025